Metabolomics and proteomics: synergistic tools for understanding snake venom inhibition.

Autor: Hussain SS; Department of Integrative Biology, School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, 632014, Tamil Nadu, India., Kingsley JD; Department of Integrative Biology, School of Bioscience and Technology, Vellore Institute of Technology (VIT), Vellore, 632014, Tamil Nadu, India. daniekingsleybio@gmail.com.
Jazyk: angličtina
Zdroj: Archives of toxicology [Arch Toxicol] 2025 Jan 06. Date of Electronic Publication: 2025 Jan 06.
DOI: 10.1007/s00204-024-03947-4
Abstrakt: Snake envenomation presents a significant global health challenge, especially in rural areas of tropical and subtropical regions. Traditional antivenom therapies face limitations related to efficacy, availability, and specificity, prompting a need for novel approaches. Recent advancements in omics technologies, particularly metabolomics and proteomics, have enhanced our understanding of snake venom composition, toxicity, and potential therapeutic strategies. Metabolomics allows for the study of metabolic changes induced by venom, providing insights into disrupted pathways and possible inhibitors. Proteomics facilitates the identification and characterization of venom proteins, unveiling their interactions with therapeutic agents. Integrative databases such as the Snake Venom Database (SVDB) and STAB Profiles enhance this research by cataloging venom components and aiding in the analysis of venom-antivenom interactions. The combined application of metabolomics and proteomics has led to the identification of crucial metabolic pathways and protein targets essential for effective venom inhibition. This review explores current advances in these fields, emphasizing the role of omics in identifying novel inhibitors and developing next-generation antivenoms. The integrated approach of metabolomics and proteomics offers a comprehensive understanding of snake venom biology, paving the way for more effective and tailored therapeutic solutions for envenomation.
Competing Interests: Declarations. Conflict of interest: All the authors declare that they have no conflict of interest concerning the publication of this paper. Ethical approval: This work does not involve the use of humans or animals.
(© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: